Trials / Recruiting
RecruitingNCT07241546
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-RAGE | Inhalation of nebulized solution |
| DRUG | Placebo | Calculated volume to match active treatment by inhalation of nebulized solution |
Timeline
- Start date
- 2026-03-30
- Primary completion
- 2027-12-01
- Completion
- 2028-04-01
- First posted
- 2025-11-21
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07241546. Inclusion in this directory is not an endorsement.